Virginia Commonweath School of Dentistry
Richmond, Virginia, 23298, United States
NCT Number: NCT01591616
To establish Oraqix is safe when used on adolescent volunteers.
Looking for future studies?
Notify Me6 year–17 year
All sexes
Interventional
Phase 4
Richmond, Virginia, 23298, United States
This is a single-center, uncontrolled, open-label, single administration patient study. Male and female subjects aged 6 through 17 years of age in need of primary tooth extraction will be recruited from the Principal Investigator's database and may be supplemented by advertising. Subjects who withdraw from the study prematurely will be replaced.
Subjects will undergo an initial screening visit at which eligibility will be determined. After completion of informed consent/assent a physical examination, vitals, 12-lead ECG, and dental examination will be conducted. A medical history will be documented and a blood sample will be collected for analysis of biochemistry, hematology and as appropriate, serum pregnancy assessment for females.
Subjects will return to the office approximately 1 to 10 days after Visit 1 for Visit 2. At Visit 2, study treatment will be administered and PK blood samples will be collected for analysis, and monitored for safety parameters. Up to a total of five cartridges of Oraqix® will be administered to the oral cavity in the area of the tooth extraction, based on the body weight of the subject. No more than five cartridges will be dispensed, since this is the maximum dose for this agent. The final sample will be collected 4 hours after administration of study material. An abbreviated dental examination will be conducted, any adverse events (AEs) will be documented and the subject will be discharged from the clinic.
All subjects will be contacted by telephone approximately 24 hours after administration of study treatment. Study personnel will enquire about the occurrence of any AEs that have occurred since leaving the office. If appropriate, further follow-up of AEs will be arranged. In the absence of any ongoing AEs requiring follow up the subject will be considered to have completed the study at the completion of the telephone call.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Appropriate dose of Oraqix based on weight will be given before tooth extraction
Other names: Oraqix periodontal gel
Time frame: 5, 10, 15, 30, 60, 90, 120, and 240 minutes
The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).
Time frame: blood draws pre-dose, 2 and 4 hours postdose
The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals.
Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose.
For each subject, phone call was made at +24h as follow up pursuant to the protocol.
Time frame: Pre-dose and every 10 minute to 240 minutes post-dose.
Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Time frame: Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
Time frame: Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Time frame: Pre-dose, 1 hour, 2 hour, 4 hour post-dose.
Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.
Dentsply International
Industry
A Phase 4 Pediatric Study to Assess the Pharmacokinetics and Safety of Oraqix Gel in Healthy Children and Adolescent Volunteers Following Tooth Extraction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07725276
Dental Deposits, Dental Plaque
Beirut, Rue de Damas, Lebanon
View Trial DetailsNCT07721428
Cardiovascular Disease, Cardiovascular Diseases
Isparta, Merkez, Turkey (Türkiye)
View Trial DetailsNCT07697963
Mouth Diseases, Periodontal Disease
View Trial DetailsNCT02894463
Mouth Diseases, Periodontal Disease
Nantes, France
View Trial Details